Psoriasis Adult Subcutaneous Recommended Dosage :
Weight Range (kilograms) | Dosage Regimen |
---|---|
less than or equal to 100 kg | 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks |
greater than 100 kg | 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks |
Psoriasis Pediatric Patients (6 to 17 years old) Subcutaneous Recommended Dosage :
Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.
Weight Range (kilograms) | Dose |
---|---|
less than 60 kg | 0.75 mg/kg |
60 kg to 100 kg | 45 mg |
greater than 100 kg | 90 mg |
Psoriatic Arthritis Adult Subcutaneous Recommended Dosage :
Psoriatic Arthritis Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage : Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.
Weight Range (kilograms) | Dosage Regimen |
---|---|
less than 60 kg | 0.75 mg/kg |
60 kg or more | 45 mg |
greater than 100 kg with co-existent moderate-to-severe plaque psoriasis | 90 mg |
Crohn's Disease and Ulcerative Colitis Initial Adult Intravenous Recommended Dosage :
A single intravenous infusion using weight-based dosing:
Weight Range (kilograms) | Recommended Dosage |
---|---|
up to 55 kg | 260 mg (2 vials) |
greater than 55 kg to 85 kg | 390 mg (3 vials) |
greater than 85 kg | 520 mg (4 vials) |
Crohn's Disease and Ulcerative Colitis Maintenance Adult Subcutaneous Recommended Dosage :
A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.